anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Gastrointestinal adenocarcinomas are often reported in South American camelids (SAC). We describe here cases of gastroduodenal adenocarcinoma in an adult alpaca (Vicugna pacos) and a llama (Llama glama); both SACs were anorectic and lethargic before death. At autopsy, a prominent and firm caudal C3-pyloric-duodenal junction with stricture and ulceration was present in both animals, as were hemorrhages in various organs and hydrothorax. Microscopically, scattered nests, cords, and tortuous acini of neoplastic epithelial cells were embedded in desmoplastic stroma and invaded the submucosa and muscle layers of the gastroduodenal junction. The mucosa was necrotic, with gram-negative rods in the alpaca and colonies of gram-positive cocci in the llama. No tumor metastases were observed. The neoplastic cells immunolabeled for pancytokeratin. Escherichia coli was isolated from the alpaca and Streptococcus lutetiensis from the llama; septicemia was the cause of death in both animals. Although adenocarcinomas arising from gastric compartments and intestinal segments have been reported in SACs, adenocarcinoma of the caudal C3-pyloric-duodenal junction has not been reported previously in these species, to our knowledge.
Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-5mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture treatment for 30 minutes.
About 25 subjects will be allocated to this group to receive metformin only, as the active comparator of semaglutide groups. Metformin used in this trial is Glucophage ( 500mg per tablet）produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
OBJECTIVES: The aim of this multicentre study was to demonstrate the safety and clinical performance of E-vita OPEN NEO Stent Graft System (Artivion, Inc.) in the treatment of aneurysm or dissection, both acute and chronic, in the ascending aorta, aortic arch and descending thoracic aorta.
METHODS: In this observational study of 12 centres performed in Europe and in Asia patients were enrolled between December 2020 and March 2022. All patients underwent frozen elephant trunk using E-vita OPEN NEO Stent Graft System. Primary end point was the rate of all-cause mortality at 30 days and secondary end points included further clinical and safety data are reported up to 3-6 months postoperatively.
RESULTS: A total of 100 patients (66.7% male; mean age, 57.7 years) were enrolled at 12 sites. A total of 99 patients underwent surgery using the E-vita OPEN NEO for acute or subacute type A aortic dissection (n = 37), chronic type A aortic dissection (n = 33) or thoracic aortic aneurysm (n = 29), while 1 patient did not undergo surgery. Device technical success at 24 h was achieved in 97.0%. At discharge, new disabling stroke occurred in 4.4%, while new paraplegia and new paraparesis was reported in 2.2% and 2.2%, respectively. Renal failure requiring permanent (>90 days) dialysis or hemofiltration at discharge was observed in 3.3% of patients. Between discharge and the 3-6 months visit, no patients experienced new disabling stroke, new paraplegia or new paraparesis. The 30-day mortality was 5.1% and the estimated 6-month survival rate was 91.6% (standard deviation: 2.9).
CONCLUSIONS: Total arch replacement with the E-vita OPEN NEO can be performed with excellent results in both the acute and chronic setting. This indicates that E-vita OPEN NEO can be used safely, including in the setting of acute type A aortic dissection.
Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
A cDNA fragment participating in the maintenance of smooth muscle differentiation is isolated with the use of a culture system of chick gizzard smooth muscle cells by using the differential display method and the subtracted hybridization method.  Using this cDNA sequence as a query, retrieval is made on cDNA sequences of Helix Research Institute (Japanese Patent Application 2000-118776) and thus a novel gene 'C-NT2RP3001495' is obtained.  The protein encoded by this gene has two WW domains participating in protein interactions in the N-terminal domain.  It is suggested that this protein binds to another protein and thus regulate the intracellular signal transduction, gene expression, etc. to thereby participate in the maintenance of the differentiation of smooth muscle cells.  This protein and a compound regulating the expression thereof are useful in developing remedies for various diseases in association with abnormality in the maintenance of smooth muscle cell differentiation.
The utility model relates to a red powder medicine thread which is in a cylindrical round shape. The diameter of the red powder medicine thread is 0.2 to 0.5cm, and the length is 1 to 15cm. The powder medicine is filled in a cylindrical body. According to illness, the utility model can be made into an ellipse shape. The utility model is an external application appliance for treating various flaccidity tubes and sinus tracts, and has the advantages of high curative effect, convenient use, simple structural design, etc. Thereby, the utility model is an ideal external application appliance for medical use.
PURPOSE:To purify a serrapeptase useful as an anti-inflammatory agent, etc., in high purity, by contacting a serrapeptase-containing solution with an acrylate- type nonionic adsorption resin, and eluting the adsorbed serrapeptase with an elutant. CONSTITUTION:A solution containing serrapeptase is made to contact with an acrylate-type nonionic adsorption resin (e.g. Diaion HP-1MG), and the adsorbed serrapeptase is eluted with an elutant, preferably an elutant containing a water-soluble salt as a solute. The adsorbent resin has preferably a surface area of about 100-500m<2>/g and a pore volume of about 0.3-1.2ml/g. The resin has strong adsorptivity to serrapeptase and the adsorbability of serrapeptase to said resin can be improved remarkably in the presence of a water-soluble salt. Accordingly, a serrapeptase having high specific activity can be produced by this process.
A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
Patients with cancers, and in particular colorectal cancers, very often present profound nutritional and/or metabolic alterations, the most spectacular being cachexia. Cachexia is a morbid syndrome characterized by rapid involuntary weight loss mainly affecting the storage tissues of adipose tissue and skeletal muscle. This global metabolic syndrome is a major contributory factor and sometimes causative factor in the failure of treatments and the death of patients. Although a major public health problem, this disease is poorly understood and for which there are no reliable biomarkers and no universally accepted treatment protocol. It therefore appears essential to better understand this disease in order to improve the well-being and survival of patients. Being a disease with a strong metabolic component, the integration of nutritional approaches is essential. Many advances have been made in recent years in the field of clinical nutrition, particularly in cancer cachexia. Clinical nutrition is a new, transversal, booming specialty.

Recent publications suggests that cancer patients, overweight or obese, may present muscle depletion, an independent predictor of overall survival. Recent results suggest that muscle atrophy is associated with more severe toxicity of anti-cancer treatments such as fluoropyrimidines, anthracyclines, combination chemotherapy, sunitinib and sorafenib. Muscle wasting is a predictive factor for therapeutic dose limitation: dose reduction, delay or definitive discontinuation of treatment. The majority of anti-cancer drugs have a limited therapeutic index. It is important to determine the factors that explain the individual variations in efficacy and toxicity, and the determination of body composition for each patient is therefore an important step in the nutritional evaluation process, and essential data for this data base.

The investigators therefore propose the development of a prospective clinico-biological database for cachexia in patients with colon cancer, can be used for research projects aimed at developing tailored patient management strategies.
Laparoscopic cholecystectomy is a type of surgery that causes moderate postoperative pain. Paracetamol and non-steroid anti-inflammatory analgesics plus opioids are the mainstay treatment options of the moderate postoperative pain. These drugs are the most common used analgesics to ameliorate this type of pain and to reduce the consumption of opioids and their side effects.

Ibuprofen is a well-known anti-inflammatory drug and has been used as an oral formula for a long time. Few studies using its new intravenous formula had been conducted to evaluate its effectiveness for mixed type of surgeries . However, its intravenous formula has not been studied for laparoscopic cholecystectomy. Therefore, this study will compare the effects of postoperative analgesic potencies of preemptive intravenous paracetamol and ibuprofen in patients undergoing laparoscopic cholecystectomy.
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Besides core ADHD symptoms (inattentiveness, hyperactivity, impulsivity), ADHD also affects the ability to perceive and process sounds. Both hypersensitivity and hyposensitivity to loud sounds are common symptoms in ADHD patients. With stimulant medication, individuals with ADHD become more tolerant of loud noise than when they were non-medicated. It remains unknown exactly how stimulant medication alters the loudness perception. The proposed study will use the acoustic reflex to objectively measure auditory sensitivity to loud sounds. The aims of this study are to evaluate auditory sensitivity in patients with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART. Eligible participants will participate in two sessions (off-med and on-med conditions) conducted on the same day. ADHD patients will be asked to come to the laboratory before taking their ADHD medication. The investigators will repeat three tests before and after taking stimulant medication. The investigators will also conduct screening tests during and between the first and second sessions. The investigators will compare a difference between the two independent groups (ADHD vs. Control) and compare a within subject difference between medication conditions (on-med vs. off-med).
The present invention relates to a capsule for treating gastrosia, particularly to a tuckahoe gastrosia capsule. Ginseng, astragalus roots, saffron, amomun fruits, white atractylodes rhizome, eaglewood, cardamom, nutagrass flatsedge rhizome, coix seeds, tuckahoe, pueraria roots, aurantii immaturus and dried orange peels are respectively washed, dried, and ground into powder to be sieved with 100 meshes. The powder is uniformly mixed with omeprazole and calcium pantothenate, and 0.3 g of powder is taken to be encapsulated. The present invention has the advantages of less admission dosage, direct absorption in vivo, rapid function, short treatment course and obvious treatment effect. Besides, the present invention overcomes the defects of slow function of traditional Chinese medicines and temporary action of western medicines. The present invention is clinically applied to thousands of patients, and the effect is obvious. Especially for various patients of gastritis, antral gastritis and duodenal bulbar ulcer, the function of the present invention is obvious. The present invention is not limited by ages, is easy to be accepted by old people and children, and is capable of being admitted with low side effect.
A substance for use in the treatment of obesity where the substance provides the scent of a food and is suitable for delivery in a device 10 from which the scent is inhaled. The scent may be of an indulgent or unhealthy but attractive foodstuff. The substance may be suitable for delivery from a substrate 113 such as cotton wool. An inhaler 102 comprising a food scent substance and a means 114 for inhaling scent from the substance. The inhaler may have a rounded first end 106 such as a hemispherical shape suitable for fitting at least partially within the user’s nostril in use. The inhaler may contain a substrate bearing the food scent substance. Also provided is a method of treating obesity through providing a food scent substance and inhaling the food scent.
In postmarketing experience, overdose with lorazepam has occurred predominantly in combination with alcohol and/or other drugs. Therefore, in the management of overdosage, it should be borne in mind that multiple agents may have been taken.

Symptoms

Overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion, paradoxical reactions, dysarthria and lethargy. In more serious cases, and especially when other drugs or alcohol were ingested, symptoms may include ataxia, hypotonia, hypotension, cardiovascular depression, respiratory depression, hypnotic state, coma, and death.

Management

General supportive and symptomatic measures are recommended; vital signs must be monitored and the patient closely observed. When there is a risk of aspiration, induction of emesis is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit drug absorption. Hypotension, though unlikely, usually may be controlled with norepinephrine bitartrate injection. Lorazepam is poorly dialyzable. Lorazepam glucuronide, the inactive metabolite, may be highly dialyzable.

The benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including “CONTRAINDICATIONS”,  “WARNINGS”, and “PRECAUTIONS” should be consulted prior to use. 

Lorazepam Tablets, USP are administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg tablets are available.

The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dose may vary from 1 to 10 mg/day.

For anxiety, most patients require an initial dose of 2 to 3 mg/day given b.i.d. or t.i.d.

For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime.

For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated.

The dosage of lorazepam tablets should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses.
Subjects belonging to this group perform a 12-week supervised exercise. The patients will follow a moderate-to-high intensity strength exercise protocol, along with the application of a cohesive bandage (bandage will only be applied in subjects with Breast Cancer-Related Lymphedema, BCRL, and not in patients at risk).
Histone lysine-specific demethylase 1 (LSD1) is hyperactive in breast cancer, which is associated with the metastasis of the tumor. Current irreversible LSD1 inhibitors are all synthesized by covalently binding to the flavin adenine dinucleotide cofactor, which often have side effects due to the high affinity for a variety of targets. Here, we identified isoforsythiaside (IFA), a natural phenylpropanoid glycoside isolated from Forsythia suspensa, as a novel covalent inhibitor of LSD1. The target ligand fishing technique and LC-MS/MS analysis identified that IFA could covalently bind to the Ser817 residue of LSD1 by α,β-unsaturated ketone moiety to block the amine oxidase-like domain of LSD1. Moreover, RBMS3/Twist1/MMP2, the downstream signaling pathway of LSD1, was activated after IFA treatment to inhibit the metastasis of MDA-MB-231 cells in vitro and in vivo. This study provided novel molecular templates for development of LSD1 covalence-binding inhibitor and laid a foundation for developing agents against breast carcinoma metastasis for targeting LSD1.
Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
Cosmetic compn. prepared from cattle or sheep foetus. To prevent falling hair or seborrhea. Cutaneous integument and/or umbilical cord tissue is removed, frozen and ground with an aq. ionic soln. containing a neutral or acid salt, acid or base, urea or phenol; optionally the paste may be given a proteolytic enzyme digestion to liberate mucopolysaccharides (poss. the active agent), but without defatting. The mixture is centrifuged, the supernatant dialysed and pptd. with abs. alc; the ppt. is washed and dried. All stages are conducted under sterile conditions and, except for the enzyme treatment, carried out at  4 deg.
The present invention is a process for coloring gelatin-based formulations involving adding a saturated fatty acid to the gelatin-based formulation along with lake pigment, whereby the saturated fatty acid is added in an amount so as to prevent cross-linking between the gelatin-based formulations and the aluminum cations released by the lake pigments. Preferably, this amount is about 10 % to about 300 % by weight of the added lake pigment content. With this process, the resulting colored gelatin exhibits acceptable machineability characteristics and disintegration. As an example, the colored gelatin produced by this process has a viscosity of less than approximately 10,000 cP  at about 60 ~C. Additionally, the present invention is a gelatin-based formulation made from the above-described process. The gelatin-based formulation includes gelatin, lake pigment(s), and a sufficient amount of fatty acid to prevent cross-linking between and the cations released from the lake pigment(s). Further, the present invention includes a dosage form that includes the described gelatin-based formulation as the sheath material. The dosage form may encapsulate a liquid, suspension, semi-solid, or solid pharmaceutical, nutritional, herbal, or personal care product, or combination thereof.
BACKGROUND: Glioma, the most frequent and malignant central nervous system (CNS) cancer, has a bad outcome. Proteasome 26S subunit ATPase 2 (PSMC2) is an essential part of the 26S proteasome and promotes the development of several tumors. However, the pathway and function of PSMC2 in glioma have not been unelucidated.
METHODS: This study analyzed PSMC2 expression in glioma tissues and its predictive significance for patients. We examined the link between PSMC2 and DNA methylation, immune cell infiltration, tumor immune cycle, immune cell homeostasis, and immune checkpoints. Subsequently, immunohistochemistry and in vitro trials were employed to validate the expression, prognostic potential, and function of PSMC2 in glioma. The mechanisms of PSMC2 in glioma were further explored.
RESULTS: Our study revealed that PSMC2 expression increased in glioma tissues contrasted with healthy tissues, and patients with high PSMC2 glioma exhibited poor overall survival (OS) compared to the low-PSMC2 group. Immune profile analysis revealed that PSMC2 was positively related to immunosuppressive cell infiltration and immune checkpoints and adversely related to the cancer immune cycle and immune cell homeostasis. In cell-based investigations, the inhibition of PSMC2 was found to effectively suppress the aggressiveness and proliferation of glioma cell lines while also enhancing cell cycle arrest and promoting cell death. Gene Set Enrichment Analysis (GSEA), Gene Set Variation Analysis (GSVA), and in vitro experiments showed that PSMC2 promoted glioma development through the PI3K/AKT/mTOR pathway.
CONCLUSIONS: PSMC2 was upregulated in glioma and promoted cancer progression by modulating the tumor immune microenvironment, cancer cell biological behavior, immune cell homeostasis, and the PI3K/AKT/mTOR pathway, providing a new option to treat glioma.
The present invention relates to the use of at least one transferrin, preferably lactoferrin, to prepare a medicament for preventing and/or treating with great effectiveness destructive inflammation affecting mucous membranes, optionally associated with states of hypoferremia and/or anemia and/or acute and chronic infections. The destructive inflammation is caused, for example, by pathological conditions during pregnancy and by infections sustained by intracellular or adhered or biofilm-protected pathogens. The invention has shown in fact a powerful antiinflammatory activity in returning state of pathological phlogosis to physiological and no longer destructive levels, accompanied by a concurrent regulatory activity on the passage of iron from tissues to circulation and on the developmentor dissemination of pathogens together with the inhibition of the forming of superoxides, which are also involved in cell damage and in destructive inflammation. The action of the transferrins described here is achieved by means of their topical and/or oral administration. If a particularly augmented effect on the states of anemia and hypoferremia is to be achieved, it is advantageous to combine the two types of oral and topical administration. A combined preparation for simultaneous, sequential or separate use is also described which comprises, as active components, a first composition for topical administration of at least one transferrin and a second composition for oral administration of at least one transferrin.
Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.